Effectiveness of Lianhua Qingwen Capsule in Treatment of Asymptomatic COVID-19 Patients: A Randomized, Controlled Multicenter Trial

• DOI: 10.1089/jicm.2021.0352
• Publication Date: 2022-11-07T17:18:15Z
• Authors: Ling Zhang; Lei Wu; Xiaolong Xu; Yadong Yuan; Rongmeng Jiang; Xixin Yan; Xin Zhang; Yong Gao; Huanxia Shang; Jing Hu; Xuerui Wang; Jianqiang Mei; Shucai Wu; Qingquan Liu
• Keywords: Capsule

Background: Asymptomatic patients are unneglected sources in propagating transmission chain due to their high viral loads. However, treatments available based on symptoms seem not applicable asymptomatic patients. In this study, the authors want estimate effectiveness of Lianhua Qingwen (LH) capsule coronavirus disease 2019 (COVID-19) Methods: A randomized controlled trial (RCT) was performed explore and safety LH treating COVID-19 Patients were control group (isolated observation) treatment (LH, 4 capsules, thrice daily) for 14 days. The primary endpoints rate time nucleic acid turning negative during isolation observation. Results: total 120 participants included full analysis set (60 each groups). Data showed that observation higher than (rate difference: 21.66%, 95% confidence interval [CI]: 4.34 37.27, p = 0.0142). have a shorter (7.5 vs. 14.5 days, 0.018). Moreover, clinical appearance lower compared with −31.67, CI: −46.83 −13.82, 0.0005). proportion confirmed mild common cases also (35.00% 66.67%, No serious adverse events documented. Conclusions: illustrated is beneficial Considering lack interventions at stage, could be considered as choice. Chinese Clinical Trial Registry: ChiCTR2100042066.